Gary Glick, Odyssey Therapeutics CEO
Exclusive: Gary Glick’s Odyssey raises $101M Series C as first immunology drugs approach the clinic
Odyssey Therapeutics has raised $101 million in a new round, as the Boston biotech prepares for its first drug candidates to soon enter the clinic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
